


The 300+ year journey of fibrodysplasia ossificans progressiva (FOP)

From first documentation to targeted treatment



References:

1. Shah ZA et al. *J Med Case Reports* 2019;13:364; 2. Huning I & Gillesen-Kaesbach G. *Mol Syndromol* 2014; 5:201–211; 3. Illingworth RS. *Archives of Disease in childhood* 1971;46:264; 4. Fairbank HAT. *J Bone Joint Surg* 1950;32B:108–116; 5. Piotto L & Taranath A. *AJUM* 2021;24:173–177; 6. IFOPA. The Center for Research in FOP & Related Disorders at University of Pennsylvania. Available at: ifopa.org/upenn_center_for_fop_research. Accessed August 2023; 7. Cohen RB et al. *J Bone Joint Surg Am* 1993;75:215–219; 8. Shore EM et al. *Nat Gen* 2006;38:525–528; 9. Kitterman JA et al. *J Neurol* 2012;259:2636–2643; 10. Pignolo RJ et al. *J Bone Miner Res* 2016;31:650–656; 11. ClinicalTrials.gov. NCT02190747. Available at: clinicaltrials.gov/ct2/show/NCT02190747. Accessed August 2023; 12. IFOPA. History of FOP. Available at: ifopa.org/history_of_fop. Accessed August 2023; 13. International Clinical Council on Fibrodysplasia Ossificans Progressiva. Available at: <https://www.iccfop.org>. Accessed August 2023; 14. Palovarotene Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215559s000lbl.pdf